pharma · Growth Hormone Deficiency, Pediatric
Ascendis Pharma
Ascendis Pharma Endocrinology Division A/S
Ascendis Pharma Endocrinology is a pharma organization headquartered in EU. Primary therapeutic focus areas include Growth Hormone Deficiency, Pediatric. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and
Palo Alto, USA HQ
2010 Founded
5 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Palo Alto, USA
- Founded
- 2010
- Employees
- 5
- Programs
- 2
- Drugs
- 7
- Patents
- 6
Once weekly subcutaneous injection of TransCon hGH
Phase 3 · small molecule · Growth Hormone Deficiency, Pediatric
Once weekly subcutaneous injection of TransCon hGH for Growth Hormone Deficiency, Pediatric is a Phase 3 program (small_molecule) at Ascendis Pharma Endocrinology Division A/S with 1 ClinicalTrials.gov record(s).
Internal code TransCon hGH CT-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Growth Hormone Deficiency, Pediatric
- Status
- completed
- Trials
- 1